Treatment of sodium channel, voltage-gated, alpha subunit (SCNA) related diseases by inhibition of natural antisense transcript to SCNA

• US 9,771,579 B2
• Filed: 06/23/2011
• Issued: 09/26/2017
• Est. Priority Date: 06/23/2010
• Status: Active Grant

• Current Assignee: CURNA, Inc. (Opko Health, Inc.)
• Original Assignee: CURNA, Inc. (Opko Health, Inc.)
• Inventors: Collard, Joseph, Khorkova Sherman, Olga, De Leon, Belinda, Coito, Carlos, Hsiao, Jane H.
• Primary Examiner(s): Poliakova-Georgantas, Kate
• Application Number:
  US13/805,745
• Publication Number:
  US 20130096183A1
• Time in Patent Office: 2,287 Days
• Field of Search: None
• CPC Class Codes: A61K 31/7088 Compounds having three or more nucleosides or nucleotides
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 1/04 for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• CPC Class Codes: A61P 13/00 Drugs for disorders of the urinary system
• CPC Class Codes: A61P 13/08 of the prostate
• CPC Class Codes: A61P 15/00 Drugs for genital or sexual disorders for disorders of sex hormones A61P5/24; Contraceptives
• CPC Class Codes: A61P 15/10 for impotence
• CPC Class Codes: A61P 21/00 Drugs for disorders of the muscular or neuromuscular system
• CPC Class Codes: A61P 21/02 Muscle relaxants, e.g. for tetanus or cramps
• CPC Class Codes: A61P 21/04 for myasthenia gravis
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/02 for peripheral neuropathies
• CPC Class Codes: A61P 25/04 Centrally acting analgesics, e.g. opioids
• CPC Class Codes: A61P 25/06 Antimigraine agents
• CPC Class Codes: A61P 25/08 Antiepileptics; Anticonvulsants
• CPC Class Codes: A61P 25/18 Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
• CPC Class Codes: A61P 25/22 Anxiolytics
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 29/02 without antiinflammatory effect
• CPC Class Codes: A61P 3/12 for electrolyte homeostasis
• CPC Class Codes: A61P 37/02 : Immunomodulators
• CPC Class Codes: A61P 43/00 : Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 5/00 : Drugs for disorders of the endocrine system
• CPC Class Codes: A61P 9/00 : Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/04 : Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
• CPC Class Codes: A61P 9/12 : Antihypertensives
• CPC Class Codes: C12N 15/113 : Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing when used in plants C12N15/8218
• CPC Class Codes: C12N 15/1138 : against receptors or cell surface proteins
• CPC Class Codes: C12N 2310/111 : spanning the whole gene, or a large part of it
• CPC Class Codes: C12N 2310/113 : targeting other non-coding nucleic acids, e.g. antagomirs
• CPC Class Codes: C12N 2310/315 : Phosphorothioates
• CPC Class Codes: C12N 2330/10 : naturally occurring
• CPC Class Codes: C12Q 1/6813 : Hybridisation assays

Abstract

The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Sodium channel, voltage-gated, alpha subunit (SCNA), in particular, by targeting natural antisense polynucleotides of Sodium channel, voltage-gated, alpha subunit (SCNA). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of SCNA.

Claims

1. A method of upregulating a function of and/or the expression of a Sodium channel, voltage-gated, alpha subunit SCN1A polynucleotide in a biological system having SEQ ID NO:

1 comprising;

contacting said biological system with at least one single stranded antisense oligonucleotide 13 to 28 nucleotides in length which targets a 13 to 28 nucleotide region of a long non-coding natural antisense polynucleotide selected from the group consisting of SEQ ID NOS;

12-28 wherein said at least one single stranded oligonucleotide has 100% sequence identity to a reverse complement of a polynucleotide comprising 13 to 28 consecutive nucleotides within the natural antisense polynucleotide of SEQ ID NO;

12 or of SEQ ID NO;

13, or of SEQ ID NO;

14, or of SEQ ID NO;

15, or of SEQ ID NO;

16, or of SEQ ID NO;

17, or of SEQ ID NO;

18, or of SEQ ID NO;

19, or of SEQ ID NO;

20, or of SEQ ID NO;

21, or of SEQ ID NO;

22, or of SEQ ID NO;

23, or of SEQ ID NO;

24, or of SEQ ID NO;

25, or of SEQ ID NO;

26, or of SEQ ID NO;

27 or of SEQ ID NO;

28;

thereby upregulating a function of and/or the expression of the Sodium channel, voltage-gated, type I, alpha subunit (SCN1A) polynucleotide wherein the at least one oligonucleotide comprises at least one oligonucleotide sequence set forth as SEQ ID NOs;

40-92.

2. A method of upregulating a function of and/or the expression of a human Sodium channel, voltage-gated, alpha subunit (SCN1A) polynucleotide having SEQ ID NO:

1 in a biological system comprising;

contacting said system with at least one single stranded antisense oligonucleotide of 13 to 30 nucleotides in length that is 100% complementary to and specifically targets a complementary region of a natural antisense polynucleotide of the Sodium channel, voltage-gated, alpha subunit (SCN1A) polynucleotide wherein said natural antisense polynucleotide is selected from the group consisting of nucleotides 1 to 1123 of SEQ ID NO;

12 and 1 to 2352 of SEQ ID NO;

13, 1 to 267 of SEQ ID NO;

14, 1 to 1080 of SEQ ID NO;

15, 1 to 173 of SEQ ID NO;

16, 1 to 618 of SEQ ID NO;

17, 1 to 871 of SEQ ID NO;

18, 1 to 304 of SEQ ID NO;

19, 1 to 293 of SEQ ID NO;

20, 1 to 892 of SEQ ID NO;

21, 1 to 260 of SEQ ID NO;

22, 1 to 982 of SEQ ID NO;

23, 1 to 906 of SEQ ID NO;

24;

thereby upregulating a function of and/or the expression of the Sodium channel, voltage-gated, alpha subunit (SCN1A) polynucleotide wherein the at least one oligonucleotide comprises at least one oligonucleotide sequences set forth as SEQ ID NOS;

31, 33, 37, 40 to 92.

3. The method of claim 2, wherein a function of and/or the expression of the Sodium channel, voltage-gated, alpha subunit (SCN1A) is increased in vivo or in vitro with respect to a control by at least 10%.

4. The method of claim 2, wherein the at least one antisense oligonucleotide targets a natural antisense sequence of a Sodium channel, voltage-gated, type I, alpha subunit (SCNIA) polynucleotide wherein the natural antisense sequence comprises SEQ ID NO:

12.

5. The method of claim 2, wherein the at least one antisense oligonucleotide targets a natural antisense polynucleotide antisense to coding sequences of an RNA polynucleotide transcribed from the Sodium channel, voltage-gated, type I, alpha subunit (SCNIA) polynucleotide.

6. The method of claim 2, wherein the at least one antisense oligonucleotide targets a natural antisense polynucleotide having overlapping and/or non-overlapping sequences with an mRNA polynucleotide of a Sodium channel, voltage-gated, type I, alpha subunit (SCNIA) polynucleotide.

7. The method of claim 2, wherein the at least one antisense oligonucleotide comprises one or more modifications selected from:

at least one modified sugar moiety, at least one modified internucleoside linkage, at least one modified nucleotide, and combinations thereof.

8. The method of claim 7, wherein the one or more modifications comprise at least one modified sugar moiety selected from:

a 2-O-methoxyethyl modified sugar moiety, a 2′

-methoxy modified sugar moiety, a 2′

-0-alkyl modified sugar moiety, a bicyclic sugar moiety, and combinations thereof.

9. The method of claim 7, wherein the one or more modifications comprise at least one modified internucleoside linkage selected from:

a phosphorothioate, alkylphosphonate, phosphorodithioate, alkylphosphonothioate, phosphoramidate, carbamate, carbonate, phosphate triester, acetamidate, carboxymethyl ester, and combinations thereof.

10. The method of claim 7, wherein the one or more modifications comprise at least one modified nucleotide selected from:

a peptide nucleic acid (PNA), a locked nucleic acid (LNA), an arabino-nucleic acid and combinations thereof.

11. The method of claim 2, wherein the at least one oligonucleotide comprises at least one oligonucleotide sequence set forth as SEQ ID NOs:

50-92.

12. The method according to claim 2 wherein the oligonucleotide is selected from SEQ ID NO:

70.